McKesson Corporation (MCK) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
McKesson shows strong short-term momentum with a 10% revenue increase and earnings beat in Q2 FY2026, supported by strategic specialty pharma growth and positive analyst upgrades (Zacks Strong Buy). Technicals confirm ~11.6% gain over 21 days, well above key moving averages, indicating near-term price appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Thin Margins ⢠Strong Cash Flow ⢠Weak Liquidity MCK combines massive revenue and strong cash generation with efficient asset use, but thin margins and a strained, low-liquidity balance sheet limit the investment case.
Price Behavior
Key Price Behavior Insights: ⢠Strong rebound ⢠Near resistance ⢠Breakout needed Support Level: $734-$740 Resistance Level: $787-$790 MCK has turned constructive over the last month, rebounding strongly from the early-June low and now testing resistance near the high-$780s, but it still needs a decisive breakout to confirm the recovery.
Sentiment & News
Key News Insights: ⢠MMS Spinout ⢠Growth Catalysts ⢠Margin Pressure McKesson's completed Apollo minority investment in Medical-Surgical Solutions advances its planned spinout while investor attention stays focused on growth catalysts and margin/pricing risks.
AI Summary
McKesson is now best viewed as a cash-generative value-unlock story rather than a pure defensive distributor, with the Apollo-backed MMS separation signaling management's willingness to surface portfolio value, but investors should still demand proof that strong free cash flow can offset razor-thin margins, negative working capital, and execution risk during the transition.
Description
McKesson Corporation is a healthcare services and distribution company operating in the United States and select international markets. Its operations span pharmaceutical distribution, medical-surgical supply logistics, and a range of technology, consulting and outsourcing services for pharmacies, specialty practices and institutional customers, while a dedicated business supports biopharma partners and supply-chain needs. The company was founded in 1833 and is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 10 | Nov 17 | MCK | McKesson Corporation | McKesson shows strong short-term momentum with a 10% revenue increase and earnings beat in Q2 FY2026, supported by strategic specialty pharma growth and positive analyst upgrades (Zacks Strong Buy). Technicals confirm ~11.6% gain over 21 days, well above key moving averages, indicating near-term price appreciation potential. | Closed | -0.5% |